Title: Combination therapy to treat sepsis due to carbapenem-resistant bacteria in adult and paediatric population: evidence and common practice
Design: Cross sectional survey, systematic reviews and network meta-analyses
Registration Number: n.a.
Primary objective: Specific objectives are:
to investigate the prescription habits and attitudes among clinicians usually dealing with CR-GNB;
to comprehensively summarize the evidence on the available antibiotic options for the treatment of sepsis due to CR-GNB, including in vitro and in vivo data, and clinical studies.
Bringing together clinical practice and data from literature, the final aim is to point out the major gaps in knowledge in order to drive the development of future studies on the most promising treatment schemes within the GARDP projects.
Interested in collaboration? Contact: Alessia Savoldi firstname.lastname@example.org
Carrara E, Savoldi A, Piddock LJV, Franceschi F, Ellis S, Sharland M, Brink AJ, Harris PNA, Levy-Hara G, Rohit A, Tsioutis C, Zayyad H, Giske C, Chiamenti M, Bragantini D, Righi E, Gorska A, Tacconelli E. Clinical management of severe infections caused by carbapenem-resistant gram-negative bacteria: a worldwide cross-sectional survey addressing the use of antibiotic combinations. Clin Microbiol Infect. 2021 May 8:S1198-743X(21)00222-6.
Scudeller L, Righi E, Chiamenti M, Bragantini D, Menchinelli G, Cattaneo P, Giske CG, Lodise T, Sanguinetti M, Piddock LJV, Franceschi F, Ellis S, Carrara E, Savoldi A, Tacconelli E. Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli. Int J Antimicrob Agents. 2021 May;57(5):106344.
Savoldi, A., Carrara, E., Piddock, L.J.V., Franceschi F., Ellis S., Chiamenti M., Bragantini D., Righi E., Tacconelli E. The role of combination therapy in the treatment of severe infections caused by carbapenem resistant gram-negatives: a systematic review of clinical studies. BMC Infect Dis 21, 545 (2021).
University of Verona (Coordinator),
GARDP Global Antibiotic Research & Development Partnership